SPECIAL DEPARTMENTS
Authors: Andrew Spillane, J. Meirion Thomas, Peter W. T. Pisters, Raphael E. Pollock, Shreyaskumar R. Patel, Robert S. Benjamin
Journal: Journal of Clinical Oncology (2000)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2000.18.8.1800 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10764441 Andrew SpillanexAndrew SpillaneSearch for articles by this author , J. Meirion ThomasxJ. Meirion ThomasSearch for articles by this author Peter W. T. PistersxPeter W. T. PistersSearch for articles by this author , Raphael E. PollockxRaphael E. PollockSearch for articles by this author , Shreyaskumar R. PatelxShreyaskumar R. PatelSearch for articles by this author , Robert S. BenjaminxRobert S. BenjaminSearch for articles by this author Show More Royal Marsden Hospital LondonUnited KingdomThe University of Texas M.D. Anderson Cancer Center HoustonTX https://doi.org/10.1200/JCO.2000.18.8.1800 First Page Full Text PDF Figures and Tables © 2000 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyResponse01042000In Reply:We read with interest the comments of Drs Spillane and Thomas regarding our recent report in the Journal of Clinical Oncology.1 Spillane and Thomas correctly point out that T1 tumor size should be defined as 5 cm or less.2 Although less than 5 cm erroneously appears in our article instead of ≤5 cm as the cut-off point for T1 tumors, we did in fact use ≤5 cm as the tumor size criterion for inclusion in our study.We would not agree with Spillane and Thomas’s interpretation of event-free outcome in our patients. Their statement that our cohort of patients has “an unexpectedly low event-free outcome” presupposes a specific outcome for these patients. As summarized in the Discussion of our article, the literature on long-term outcome for patients with this stage disease is quite limited. The only large study of T1 soft tissue sarcomas reported to date is that of Geer et al,3 who reported somewhat higher disease-free and overall survival rates at a median follow-up of 42 months than we found at a median of 76 months. Certainly, the longer follow-up in our series and the well-described phenomenon of late recurrence of soft tissue sarcoma4 may contribute to the differences between our observations and the outcome expected by Spillane and Thomas.Spillane and Thomas state that the distribution of superficial versus deep lesions in our site- and stage-specific report is not comparable to “most series of extremity STS.” Unfortunately, they do not provide any references to indicate which reports they have compared our series to and whether or not those reports were stage-specific. Thus, it is difficult to respond precisely to their statement regarding generalization of our conclusions. Given the significant limitations associated with comparison of single-institution retrospective series from different referral-based populations and the relative paucity of series reporting size-, site-, and stage-specific distributions of clinicopathologic factors, the frequency of superficial versus deep lesions in our report seems relatively similar to stage-specific3 and site-specific reports from other groups.5-8 Nonetheless, we would suggest caution in interpretation of the distribution of prognostic factors in referral-based populations such as our own. It is difficult, if not impossible, to predict the anticipated distribution of prognostic factors within a specific cohort of patients accrued in a referral setting.We also disagree with the assertion that inclusion of a greater fraction of patients with superficial lesions accounts for what Spillane and Thomas perceive as an unexpectedly low event-free outcome. Indeed, given the well-established better prognosis of patients with T1a lesions,5,6,10 one would postulate exactly the opposite, ie, that our cohort of patients should have improved outcome with the inclusion of a larger fraction of patients with T1a lesions.With regard to the issues raised by Spillane and Thomas regarding the fifth edition of the American Joint Committee on Cancer Staging Manual, we agree that improvements in the current staging system are needed. This point has also been articulately advanced, with supporting data, in a recent editorial by Brennan.9 We would not, however, agree that depth is a “relatively inconsequential variable.” Tumor depth relative to the investing fascia has been demonstrated to have independent prognostic significance in several recent prognostic factor analyses.5,6,10 Spillane and Thomas may be less familiar with this because depth was omitted from a recent analysis of soft tissue sarcoma prognostic factors from their institution.11We agree with Spillane and Thomas that important observations can be made from retrospective studies. In this regard, the most important observations from our study seem to be: (1) there is a subset of patients with T1 high-grade sarcomas who have a poor prognosis that seems to approach that of other patients with traditional high-risk extremity sarcomas, and (2) long-term follow-up is important (even for patients with ostensibly early-stage sarcoma), since 15% of recurrences were observed beyond 5 years of follow-up. 2. Fleming JB, Berman R, Cheng S, et al: Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcoma. J Clin Oncol 17::2772,1999-2780, Link, Google Scholar2. Soft tissue sarcoma, in Fleming ID, Cooper JS, Henson DE, et al (eds): American Joint Committee on Cancer Staging Manual (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 149-156 Google Scholar2. Geer RJ, Woodruff JM, Casper ES, et al: Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg 127::1285,1992-1289, Crossref, Medline, Google Scholar2. Lewis JJ, Leung DHY, Casper ES, et al: Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg 134::190,1999-194, Crossref, Medline, Google Scholar2. Gaynor JJ, Tan CC, Casper ES, et al: Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: A study of 423 adults. J Clin Oncol 10::1317,1992-1329, Link, Google Scholar2. Pisters PWT, Leung DHY, Woodruff JM, et al: Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14::1679,1996-1689, Link, Google Scholar2. Rydholm A, Gustafson P, Rooser B, et al: Limb-sparing surgery without radiotherapy based on anatomic location of soft tissue sarcoma. J Clin Oncol 9::1757,1991-1765, Link, Google Scholar2. Baldini EH, Goldberg J, Jenner C, et al: Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 17::3252,1999-3259, Link, Google Scholar2. Brennan MF: Staging of soft tissue sarcomas. Ann Surg Oncol 6::8,1999-9, (editorial) Crossref, Medline, Google Scholar2. Coindre JM, Terrier P, Bui NB, et al: Prognostic factors in adult patients with locally controlled soft tissue sarcoma: A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 14::869,1996-877, Link, Google Scholar2. Ramanathan RC, A’Hern R, Fisher C, et al: Modified staging system for extremity soft tissue sarcomas. Ann Surg Oncol 6::57,1999-69, Crossref, Medline, Google Scholar